78 citations
,
June 2022 in “Infection” Many COVID-19 survivors experience long-term symptoms like fatigue and sleep issues, needing ongoing medical support.
5 citations
,
October 2021 in “American Journal of Medical Genetics Part A” A new genetic variant causes BRESHECK syndrome by disrupting cell growth and stress response.
54 citations
,
October 2019 in “Cochrane library” Some drugs may reduce prostatitis symptoms short-term with few side effects.
20 citations
,
December 2021 in “Journal of the American Academy of Dermatology” Continuous treatment with ritlecitinib and brepocitinib is needed to maintain hair regrowth in alopecia areata.
Potassium channel openers like minoxidil boost hair growth.
April 2017 in “Journal of Investigative Dermatology” Cholecystokinin may help reduce skin inflammation in psoriasis.
March 2026 in “Journal of Multidisciplinary Applied Natural Science” Cosmos caudatus extract is as effective as finasteride for treating benign prostatic hyperplasia without its side effects.
December 2024 in “Clinical and Experimental Dermatology” Switching to ritlecitinib improves hair regrowth and well-being in severe alopecia areata patients.
62 citations
,
January 2004 in “PubMed” 5alpha-reductase inhibitors like finasteride and dutasteride effectively treat BPH by reducing DHT, offering symptom relief and potential future uses.
13 citations
,
January 1987 in “Dermatology” Minoxidil sulfate relaxes blood vessels by increasing potassium permeability.
27 citations
,
August 2024 in “Frontiers in Pharmacology” Tralokinumab for atopic dermatitis may cause side effects like dizziness, headache, nausea, hair loss, and acne.
March 2009 in “European Urology Supplements” 26 citations
,
December 2023 in “Prostate International” Medications for BPH can have significant side effects, so understanding these risks is important for treatment decisions.
January 2024 in “Journal of Clinical Images and Medical Case Reports” Baricitinib may help treat frontal fibrosing alopecia and facial papules.
37 citations
,
October 2017 in “Clinical and Experimental Dermatology” Oral tofacitinib shows promise in treating atopic dermatitis and alopecia areata, but only slight improvement in vitiligo.
4 citations
,
June 2020 in “Processes” Geranium sibiricum may help manage diabetic complications by inhibiting a key enzyme.
1707 citations
,
December 2003 in “The New England Journal of Medicine” Combination therapy of doxazosin and finasteride safely and effectively reduces benign prostatic hyperplasia progression risk.
May 2026 in “Chemical Engineering Journal” 27 citations
,
May 2016 in “Integrative Cancer Therapies” Chrysin makes docetaxel more effective and reduces its side effects in lung cancer treatment.
January 2025 in “International Journal of Molecular Sciences” Fenugreek extract may help treat benign prostatic hyperplasia.
1 citations
,
April 2016 in “Journal of The American Academy of Dermatology” Blood pressure medications may increase the risk of skin cancer.
1 citations
,
March 2023 in “Science Translational Medicine” Blocking a certain signal in the gp130 receptor can improve tissue healing and lessen osteoarthritis symptoms.
14 citations
,
June 2015 in “Toxicology and Industrial Health” Low doses of BPA can increase prostate growth and change hormone levels in adult rats.
3 citations
,
July 2024 in “Journal of the American Academy of Dermatology” Dermatologists are hesitant to prescribe Janus kinase inhibitors for alopecia areata due to safety concerns and lack of knowledge.
November 2021 in “bioRxiv (Cold Spring Harbor Laboratory)” 4-aminopyridine helps skin wounds heal faster and better.
May 2024 in “Journal of molecular structure” A new compound, 3a, effectively fights prostate cancer better than finasteride.
April 2017 in “Journal of Investigative Dermatology” SM04755 may be an effective topical treatment for psoriasis.
36 citations
,
December 2021 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology” Two drugs, ritlecitinib and brepocitinib, improved scalp hair loss condition markers.
July 2022 in “Dermatologic Therapy”
45 citations
,
August 2010 in “Hormone Molecular Biology and Clinical Investigation” Type 3 5α-reductase is more common and finasteride and dutasteride strongly inhibit it.